XML 52 R43.htm IDEA: XBRL DOCUMENT v2.4.0.8
ALLIANCES AND COLLABORATIONS (Lilly) (Details) (USD $)
In Millions, unless otherwise specified
3 Months Ended 6 Months Ended
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2013
Jun. 30, 2012
Dec. 31, 2012
Alliances and Collaborations Statement [Line Items]          
Net Sales $ 4,048 $ 4,443 $ 7,879 $ 9,694  
Amortization expense - upfront, milestone and other licensing payments     431 203  
Other (income)/expense 199 (51) 180 (235)  
Other intangible assets - upfront, milestone and other licensing payments 8,370   8,370   8,778
Erbitux [Member]
         
Alliances and Collaborations Statement [Line Items]          
Net Sales 171 179 333 358  
Lilly [Member] | Upfront, milestone and other licensing payments [Member]
         
Alliances and Collaborations Statement [Line Items]          
Amortization expense - upfront, milestone and other licensing payments 10 9 19 19  
Other intangible assets - upfront, milestone and other licensing payments 192   192   211
Lilly [Member] | Erbitux [Member]
         
Alliances and Collaborations Statement [Line Items]          
Net Sales   179   358  
Lilly [Member] | Erbitux [Member] | Upfront, milestone and other licensing payments [Member]
         
Alliances and Collaborations Statement [Line Items]          
Total upfront, milestone and other licensing payments 500   500    
Lilly [Member] | Erbitux [Member] | North America [Member]
         
Alliances and Collaborations Statement [Line Items]          
Distribution fee, percentage of net sales 39.00%   39.00%    
Distribution fees and royalty expense 71 75 138 149  
Lilly [Member] | necitumumab [Member]
         
Alliances and Collaborations Statement [Line Items]          
Research and development reimbursements to/(from) collaboration partner   7   8  
Lilly [Member] | Byetta And Bydureon [Member]
         
Alliances and Collaborations Statement [Line Items]          
Reversal of obligation to collaboration partner for non-U.S. losses during a transition period     21    
Lilly [Member] | Byetta And Bydureon [Member] | Non United States [Member]
         
Alliances and Collaborations Statement [Line Items]          
Maximum amount payable to alliance partner for losses     60    
Lilly and Merck KGaA [Member] | Erbitux [Member] | Japan [Member]
         
Alliances and Collaborations Statement [Line Items]          
Percentage share of pre-tax profit/loss received from the net sales of a collaboration partner to be shared further equally with another collaboration partner. 50.00%   50.00%    
Lilly and Merck KGaA [Member] | Erbitux [Member] | Japan [Member] | Commercialization fee [Member]
         
Alliances and Collaborations Statement [Line Items]          
Other (income)/expense $ (8) $ (13) $ (12) $ (19)